Non-typhoidal salmonella (NTS) bacteremia is a significant cause of morbidity and mortality in HIV-infected individuals worldwide. Recent reports have noted increasing resistance of NTS isolates to fluoroquinolones, the recommended first-line therapy for NTS bacteremia. The outcomes and risk factors for NTS bacteremia in HIV-infected patients in an urban US setting were evaluated. From January 2002 to December 2006, 26 episodes of NTS bacteremia were identified in 16 patients. The risk factors for NTS bacteremia were low CD4 count, high viral load, and lack of antiretroviral therapy (ART). Recurrences appeared related to lack of immune reconstitution in patients not on ART. Unlike reports from Asia, no fluoroquinolone resistance was identified in any of the Salmonella strains isolated in this setting. Optimal treatment of NTS in the HIV-infected patient in the United States should include therapy with fluoroquinolones as well as attaining complete viral suppression and immune reconstitution with ART.
Introduction
Non-typhoidal salmonella (NTS) have been well described as a significant cause of bacteremia in HIV-infected children and adults worldwide and are commonly associated with high morbidity, mortality, and recurrence of bacteremia. [1] [2] [3] [4] [5] [6] [7] In the United States, the majority of cases of Salmonella bacteremia are caused by non-typhoidal strains. Non-typhoidal salmonella bacteremia has been demonstrated to occur more frequently in HIV-infected patients compared to the general population 8 and is more likely to occur in HIV-infected patients with advanced disease. [9] [10] [11] [12] In patients living with AIDS, NTS bacteremia has a predilection for recurrence and recurrent NTS bacteremia remains a diagnostic indicator of AIDS according to the US Centers for Disease Control and Prevention (CDC) criteria. 13, 14 Prior to the introduction of highly active antiretroviral therapy (HAART), the recurrence rate of NTS bacteremia was as high as 45%. 5, 9 Zidovudine (ZDV) monotherapy was then documented in a small number of patients to protect against recurrences of NTS bacteremia. 12 Subsequently, a few reports have noted improvement in outcomes and fewer recurrences of NTS bacteremia when HIV-infected patients were treated with HAART, even in the presence of fluoroquinolone resistance. 15, 16 The preferred agents for treatment and, subsequently, prophylaxis of NTS bacteremia in HIV-infected patients have been the fluoroquinolones. 17 However, recent reports from Asia and other regions have demonstrated an increasing incidence of fluoroquinolone resistance, as high as 34% in one case series of Salmonella enterica serotype Choleraesuis strains, with NTS isolates. 6, 15, [18] [19] [20] [21] 22 This leads to concern as to the optimal therapy and prophylaxis of NTS bacteremia in HIV-infected patients in other areas with a high incidence of HIV infection. The Baltimore metropolitan area had the second highest incident AIDS case report rate of any major metropolitan area in the United States in 2006. 23 This study reviews the experience with NTS bacteremia in HIV-infected patients during the HAART era at a large urban medical center in Baltimore.
Patients and Methods

Study Population
This was a retrospective chart review of all HIV-infected patients with cultures positive for NTS from January 2002 to December 2006, at the University of Maryland Medical Center (UMMC), is a 600-bed teaching institution in downtown Baltimore, with a dedicated HIV inpatient service that has over 1100 HIV-related admissions per year. The study was approved by the University of Maryland's Institutional Review Board.
Clinical and Laboratory Evaluations
Blood cultures were drawn per standard hospital policy from 2 separate sites and collected in blood culture bottles (BacTAlert, Becton Dickinson, Maryland). The cultures were placed in a continuous automated detection incubator (BacT/Alert), they were then plated onto standard growth media as per standard laboratory protocol, and susceptibilities were performed using the disk diffusion method (Kirby Bauer) following the Clinical and Laboratory Standards Institute (CLSI) guidelines. 24 Differentiation of Salmonella typhi from NTS strains was performed using CLSI guidelines.
Data Collection and Analysis
Information on study participants was collected by chart review and included age, sex, end stage renal disease, hepatitis C virus (HCV) infection, and other comorbid conditions, total length of stay (LOS), CD4 count and HIV RNA level during admission, HAART used, antimicriobial susceptibilities of the isolates, initial and discharge antimicrobial therapy and duration of therapy, and any surgery. In addition, information on recurrence of NTS bacteremia was recorded along with susceptibility profiles and survival status at the end of antimicrobial therapy. As this was a retrospective chart review with a relatively small study population, data were summarized and reported.
Results
Participant Characteristics
There were 4206 patient admissions to UMMC, with an HIV diagnosis during the study time period. Among these admissions, there were a total of 28 episodes of Salmonella bacteremia occurring in 18 HIV-infected patients. Twenty-six of these episodes were caused by NTS strains and occurred in 16 patients. Therefore, the rate of NTS bacteremia per admission in HIV-infected patients to UMMC was 0.3 per HIV admission and the overall rate was 0.03 episodes/1000 patient days, which is about 100 times less than our rate of Staphylococcus aureus bacteremia infections over the same time period (unpublished data, Graeme Forrest, M.B.B.S., 2008). Baseline demographics of these 16 patients are recorded in Table 1 . Co-infection with HCV and intravenous drug use was present in the majority of patients, 14 (88%) of the 16 patients. Although the median CD4 count was 31 (Â10 6 cells/mm 3 ), 3 of 16 patients (19%) had a CD4 count >200 cells/mm 3 . All patients had uncontrolled viral loads with a median HIV RNA of 105 000 copies/mL. Three patients, all with CD4 counts <20 cells/mm 3 , also had NTS isolated from an additional site; all 3 had urinary tract infections.
Recurrence of Bacteremia
Recurrence of NTS bacteremia occurred in 4 patients, ranging from 14 to 180 days post discharge from hospital, with their median CD4 count and viral load being 17 (Â10 6 cells/mm 3 ) (range 4-117) and 458 000 copies/mL (range 97 500 to >750 000), respectively. Two patients had 1 recurrence each, 1 patient had 2 recurrences and 1 patient had 6 episodes of NTS bacteremia, despite having an elective cholecystectomy following the fourth episode. This patient continued to have recurrent NTS bacteremia whenever quinolone therapy was stopped and ultimately died, with mortality attributed to NTS infection. This patient persistently refused antiretroviral therapy (ART) despite recommendations for treatment. The only other patient death was unrelated to NTS bacteremia. All 4 patients with NTS recurrence underwent transthoracic and/or transesophageal echocardiograms, which did not identify a cardiac source and the patients had no other evidence of metastatic foci.
Susceptibilities
Of the NTS isolates from the 16 patients, there were 14 Salmonella enterica serotype enteritidis, 1 serotype typhimurium, and 1 serotype oranienberg. All the NTS isolates were sensitive to ampicillin, quinolones, ceftriaxone, and trimethoprimsulfamthoxazole, except for one isolate that was resistant to ampicillin initially. All isolates in patients with recurrent infection retained their original susceptibility profiles despite quinolone treatment. Overall, patients were treated with a quinolone for a median of 28 days (range 10-300 days).
Impact of HAART
There were only 4 (25%) patients on HAART therapy at time of NTS bacteremia and none had HIV viral suppression. All recurrences of infection occurred in patients not receiving HAART and those without viral suppression. The major reason for not resuming HAART in these patients was nonadherence to therapy, which suggests that perhaps the recurrent infections may have been due to nonadherence to quinolone therapy. This could be supported by the fact that the follow-up susceptibility profiles of the organisms were unchanged.
Discussion
Unlike reports from resource-limited settings, 1-5 NTS bacteremia remains an uncommon cause of bacteremia in HIVinfected patients in an urban setting in the United States, with a high incidence and prevalence of HIV infection. In this setting, NTS bacteremia appeared to be associated with a diagnosis of AIDS, high HIV viral load, not taking HAART, and HCV coinfection, which is similar to reported risk factors in resource-limited settings. 3, 15 However, in contrast to reports in other settings, all of the NTS isolates in this study were susceptible to standard antibiotic therapy. It is quite likely that this difference is influenced by the differences in NTS serotypes. The predominant serotype in our population was Salmonella enterica serotype enteritidis, whereas recent reports of NTS isolates from Asia have demonstrated high levels of resistance with choleraesuis strains. 15 As has been previously suggested, the choice of optimal therapy for NTS bacteremia may need to be directed by knowledge of the geographic region and susceptibilities of isolates in that region. 15 Recurrences of NTS bacteremia appeared to be associated with not taking HAART and, possibly, with nonadherence to antibiotic therapy. The primary reason for providers not treating patients in this study with ART was due to problems with adherence, either with medication, clinic appointments, or both. Despite this, only 1 death was attributable to recurrent NTS bacteremia. In this patient, no obvious endovascular source was identified. The mortality of NTS bacteremia in this small study was much lower than has been reported by other groups. 15 This may be due to the transient immunologic benefits of intermittent HAART or earlier identification and treatment of bacteremia. Of note, 1 patient had recurrent NTS even after cholecystectomy, suggesting that alternative sources of infection other than the gallbladder should be considered. This and other studies of NTS suggest that, although the fluoroquinolones are effective antimicrobial therapy, reconstituting the immune system through the initiation or re-initiation of ART is vital to prevent infection and relapses. 17, 20, 21 Non-typhoidal salmonella bacteremia is an uncommon infection in HIV patients in an urban US setting, however infections appear related to AIDS status, CD4 count, HAART use, and HIV RNA viral load. Resistance to fluoroquinolones was not identified even in recurrent cases. These data support the CDC/Infectious Diseases Society of America (IDSA) recommendations for the treatment of Salmonella bacteremia in the HIV-infected patient in the United States. 17 Optimal treatment of NTS in the HIV-infected patient should include attaining complete viral suppression and immune reconstitution with HAART as well as fluoroquinolone therapy in geographic regions with susceptible NTS isolates.
